A Survey of Quality Attributes of Virus Spike Preparations Used in Clearance Studies

References

1. 1.↵
   FDA. Points To Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Department of Health and Human Services, Food and Drug Administration, Rockville, MD USA, 1997.
2. 2.↵
   EMEA. Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products. Committee for Proprietary Medical Products, European Medicines Evaluation Agency, London, UK, 2006.
3. 3.↵
   ICH. Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, Q5A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva Switzerland, 1999.
4. 4.↵
   1. Miesegaes G.,
   2. Lute S.,
   3. Brorson K.

   Analysis of viral clearance unit operations from monoclonal antibody regulatory submissions. Biotechnol. Bioeng. 2010, 106 (2), 238–246.

   OpenUrlPubMed
5. 5.↵
   PDA Technical Report 47: Preparation of Virus Spikes Used for Virus Clearance Studies. Bethesda, MD USA: Parenteral Drug Association, 2010.
6. 6.↵
   1. Bolton G.,
   2. Cabatingan M.,
   3. Rubino M.,
   4. Lute S.,
   5. Brorson K.,
   6. Bailey M.

   Normal-flow virus filtration: detection and assessment of the endpoint in bio-processing. Biotechnol. Appl. Biochem. 2005, 42 (Pt. 2), 133–142.

   OpenUrlPubMed
7. 7.↵
   1. Cabatingan M.

   Impact of virus stock quality on virus filter validation: A case study. Bioprocess Int. 2005, 3 (10), S39–S43.

   OpenUrl
8. 8.↵
   1. Asher D.,
   2. Slocum A.,
   3. Bergmann K.,
   4. Genest P.,
   5. Katz A.,
   6. Morais J.,
   7. Lawrence C.,
   8. Greenhalgh P.

   Predicting virus filtration performance with virus spike characterization. Biopharm Int. 2011, 9, 26–37.

   OpenUrl
9. 9.↵
   1. Lute S.,
   2. Wang H.,
   3. Sanchez D.,
   4. Barletta J.,
   5. Chen Q.,
   6. Brorson K.

   Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production. Biologicals 2009 37 (5), 331–337.

   OpenUrlPubMed
10. 10.↵
    1. Shi L.,
    2. Chen Q.,
    3. Norling L. A.,
    4. Lau A. S.,
    5. Krejci S.,
    6. Xu Y.

    Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification. Biotechnol. Bioeng. 2004, 87 (7), 884–896.

    OpenUrlPubMed
11. 11.↵
    1. Ma W.,
    2. Lager K. M.,
    3. Richt J. A.,
    4. Stoffregen W. C.,
    5. Zhou F.,
    6. Yoon K. J.

    Development of real-time polymerase chain reaction assays for rapid detection and differentiation of wild-type pseudorabies and gene-deleted vaccine viruses. J. Vet. Diagn. Invest. 2008, 20 (4), 440–447.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Uchiyama A.,
    2. Besselsen D. G.

    Detection of Reovirus type 3 by use of fluorogenic nuclease reverse transcriptase polymerase chain reaction. Lab. Anim. 2003, 37 (4), 352–359.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Ausubel F.,
    2. Brent R.,
    3. Kingston R.,
    4. Moore D.,
    5. Seidman J.,
    6. Smith J.,
    7. Struhl K.

    Analysis of Proteins. In Current Protocols in Molecular Biology; John Wiley and Sons, Inc.: Hoboken, NJ, 1997.
14. 14.↵
    1. Brorson K.,
    2. Krejci S.,
    3. Lee K.,
    4. Hamilton E.,
    5. Stein K.,
    6. Xu Y.

    Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol. Bioeng. 2003, 82 (3), 321–329.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Lute S.,
    2. Bailey M.,
    3. Combs J.,
    4. Sukumar M.,
    5. Brorson K.

    Phage passage after extended processing in small-virus-retentive filters. Biotechnol. Appl. Biochem. 2007, 47 (Pt. 3), 141–151.

    OpenUrlPubMed
16. 16.↵
    1. Brorson K.,
    2. De Wit C.,
    3. Hamilton E.,
    4. Mustafa M.,
    5. Swann P. G.,
    6. Kiss R.,
    7. Taticek R.,
    8. Polastri G.,
    9. Stein K. E.,
    10. Xu Y.

    Impact of cell culture process changes on endogenous retrovirus expression. Biotechnol. Bioeng. 2002, 80 (3), 257–267.

    OpenUrlPubMed
17. 17.↵
    1. Brorson K.,
    2. Brown J.,
    3. Hamilton E.,
    4. Stein K. E.

    Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr., A 2003, 989 (1), 155–163.

    OpenUrlPubMed